Impact of Smoking History on Response to Immunotherapy in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Sep 9

PMID 34497760

Citations 25

Authors

Wenhua Zhao

Wei Jiang

Huilin Wang

Jianbo He

Cuiyun Su

Qitao Yu

Affiliations

Soon will be listed here.

Abstract

Objectives: To evaluate the impact of smoking history on the clinical benefit of immunotherapy in patients with non-small cell lung cancer (NSCLC).

Methods: Twenty-three randomized clinical trials and seven real-world studies were included in this meta-analysis. Hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival (OS) and progression-free survival (PFS) and odds ratios for the overall response rate (ORR) were extracted. A fixed-effects or random-effects model was applied to obtain pooled estimates.

Results: Data from 16 high-quality trials involving 10,643 NSCLC patients receiving either immunotherapy or chemotherapy/placebo enabled direct comparison of the survival impact of smoking. Anti-PD-1/PD-L1/CTLA-4 immunotherapy was found to significantly prolong OS and PFS as compared to chemotherapy/placebo in smokers (HR for OS, 0.76 [0.69-0.83], P<0.00001; HR for PFS, 0.65 [0.56-0.75], P<0.00001), and these trends were less or not significant in non-smokers (HR for OS, 0.91 [0.78-1.06], P=0.25; HR for PFS, 0.68 [0.45-1.03], P=0.07). Consistent results were obtained for the first-line or second/third-line use of immunotherapy and for non-squamous NSCLC patients only. Furthermore, the data from 7 trials and 7 real-world studies involving 4,777 patients receiving immunotherapy allowed direct comparison of therapeutic outcomes between smokers and non-smokers. Prolonged OS (HR 0.86 [0.75-0.99], P=0.04) and PFS (HR 0.69 [0.60-0.81], P<0.0001) and a higher response rate (ORR 1.20 [0.94-1.53], P=0.15) were observed in smokers compared to non-smokers receiving immunotherapy.

Conclusions: Immunotherapy was found to have a greater benefit in NSCLC patients with a smoking history than in those who had never smoked.

Citing Articles

KRASG12D drives immunosuppression in lung adenocarcinoma through paracrine signaling.

Lasse-Opsahl E, Barravecchia I, McLintock E, Lee J, Ferris S, Espinoza C JCI Insight. 2025; 10(1.

PMID: 39782689 PMC: 11721295. DOI: 10.1172/jci.insight.182228.

Immunotherapy in Non-Small-Cell Lung Cancer: A Modified Delphi Survey Consensus on First Line Treatment, Special Populations and Rechallenge.

Colonese F, Bulotta A, Genova C, Signorelli D, Bonanno L, Proto C Biomedicines. 2025; 12(12.

PMID: 39767647 PMC: 11727585. DOI: 10.3390/biomedicines12122742.

Sex differences in the pharmacokinetics of anticancer drugs: a systematic review.

Delahousse J, Wagner A, Borchmann S, Adjei A, Haanen J, Burgers F ESMO Open. 2024; 9(12):104002.

PMID: 39662226 PMC: 11697095. DOI: 10.1016/j.esmoop.2024.104002.

Association between smoking status, toxicity and survival in the checkpoint inhibitor immunotherapy.

Rudzinska A, Juchaniuk P, Oberda J, Krukowska K, Krzyskowska S, Kuchta E Front Oncol. 2024; 14:1459608.

PMID: 39655067 PMC: 11625667. DOI: 10.3389/fonc.2024.1459608.

Real-World Clinical Outcomes of Neoadjuvant Platinum-Based Chemotherapy with Nivolumab in Non-Small Cell Lung Cancer.

Shalata W, Daher S, Maimon Rabinovitch N, Shamai S, Kian W, Turgeman I J Clin Med. 2024; 13(21).

PMID: 39518706 PMC: 11546520. DOI: 10.3390/jcm13216568.

References

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

Norum J, Nieder C . Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature. ESMO Open. 2018; 3(6):e000406. PMC: 6173248. DOI: 10.1136/esmoopen-2018-000406. View

Adderley H, Blackhall F, Lindsay C . KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition. EBioMedicine. 2019; 41:711-716. PMC: 6444074. DOI: 10.1016/j.ebiom.2019.02.049. View

Jung K, Jeon C, Jee S . The effect of smoking on lung cancer: ethnic differences and the smoking paradox. Epidemiol Health. 2017; 38:e2016060. PMC: 5309724. DOI: 10.4178/epih.e2016060. View

Govindan R, Szczesna A, Ahn M, Schneider C, Gonzalez Mella P, Barlesi F . Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2017; 35(30):3449-3457. DOI: 10.1200/JCO.2016.71.7629. View

Nishio M, Takahashi T, Yoshioka H, Nakagawa K, Fukuhara T, Yamada K . KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer. Cancer Sci. 2019; 110(3):1012-1020. PMC: 6398876. DOI: 10.1111/cas.13932. View

Smolle E, Pichler M . Non-Smoking-Associated Lung Cancer: A distinct Entity in Terms of Tumor Biology, Patient Characteristics and Impact of Hereditary Cancer Predisposition. Cancers (Basel). 2019; 11(2). PMC: 6406530. DOI: 10.3390/cancers11020204. View

Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, de Marinis F . Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol. 2018; 19(11):1468-1479. DOI: 10.1016/S1470-2045(18)30673-9. View

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

10.

Lee K, Lord S, Kasherman L, Marschner I, Stockler M, Gralla R . The impact of smoking on the effectiveness of immune checkpoint inhibitors - a systematic review and meta-analysis. Acta Oncol. 2019; 59(1):96-100. DOI: 10.1080/0284186X.2019.1670354. View

11.

Morita R, Okishio K, Shimizu J, Saito H, Sakai H, Kim Y . Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan. Lung Cancer. 2019; 140:8-18. DOI: 10.1016/j.lungcan.2019.11.014. View

12.

Li X, Li J, Wu P, Zhou L, Lu B, Ying K . Smoker and non-smoker lung adenocarcinoma is characterized by distinct tumor immune microenvironments. Oncoimmunology. 2018; 7(10):e1494677. PMC: 6169585. DOI: 10.1080/2162402X.2018.1494677. View

13.

Chen M, Li Q, Xu Y, Zhao J, Zhang L, Wei L . Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis. Thorac Cancer. 2020; 11(7):1955-1962. PMC: 7327684. DOI: 10.1111/1759-7714.13488. View

14.

Sharpnack M, Cho J, Johnson T, Otterson G, Shields P, Huang K . Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung Cancer. Lung Cancer. 2020; 146:36-41. DOI: 10.1016/j.lungcan.2020.05.021. View

15.

Nagahashi M, Sato S, Yuza K, Shimada Y, Ichikawa H, Watanabe S . Common driver mutations and smoking history affect tumor mutation burden in lung adenocarcinoma. J Surg Res. 2018; 230:181-185. PMC: 10389245. DOI: 10.1016/j.jss.2018.07.007. View

16.

Fisher D, Carpenter J, Morris T, Freeman S, Tierney J . Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach?. BMJ. 2017; 356:j573. PMC: 5421441. DOI: 10.1136/bmj.j573. View

17.

Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

18.

Yang D, Chen C . Cigarette Smoking-Mediated Macrophage Reprogramming: Mechanistic Insights and Therapeutic Implications. J Nat Sci. 2019; 4(11). PMC: 6383770. View

19.

Nishio M, Hida T, Atagi S, Sakai H, Nakagawa K, Takahashi T . Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer. ESMO Open. 2017; 1(4):e000108. PMC: 5566979. DOI: 10.1136/esmoopen-2016-000108. View

20.

Chae Y, Davis A, Raparia K, Agte S, Pan A, Mohindra N . Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2018; 20(2):88-96.e6. DOI: 10.1016/j.cllc.2018.09.008. View